Risk Factors of Daptomycin-Induced Eosinophilic Pneumonia in a Population with Osteoarticular Infection

被引:15
作者
Soldevila-Boixader, Laura [1 ,2 ]
Villanueva, Bernat [1 ]
Ulldemolins, Marta [1 ]
Benavent, Eva [1 ,2 ]
Padulles, Ariadna [3 ]
Ribera, Alba [1 ,2 ]
Borras, Irene [1 ]
Ariza, Javier [1 ,2 ,4 ]
Murillo, Oscar [1 ,2 ,4 ]
机构
[1] IDIBELL Hosp Univ Bellvitge, Infect Dis Serv, Feixa Llarga S-N, Barcelona 08907, Spain
[2] Bone & Joint Infect Study Grp Spanish Soc Clin Mi, Madrid 28003, Spain
[3] IDIBELL Hosp Univ Bellvitge, Pharm Dept, Feixa Llarga S-N, Barcelona 08907, Spain
[4] Inst Salud Carlos III, Spanish Network Res Infect Dis REIPI RD16 0016 00, Madrid 28029, Spain
来源
ANTIBIOTICS-BASEL | 2021年 / 10卷 / 04期
关键词
daptomycin; eosinophilic pneumonia; risk factors; PROSTHETIC JOINT INFECTION; EFFICACY; RIFAMPIN; SAFETY; BONE;
D O I
10.3390/antibiotics10040446
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Background: Daptomycin-induced eosinophilic pneumonia (DEP) is a rare but severe adverse effect and the risk factors are unknown. The aim of this study was to determine risk factors for DEP. Methods: A retrospective cohort study was performed at the Bone and Joint Infection Unit of the Hospital Universitari Bellvitge (January 2014-December 2018). To identify risk factors for DEP, cases were divided into two groups: those who developed DEP and those without DEP. Results: Among the whole cohort (n = 229) we identified 11 DEP cases (4.8%) and this percentage almost doubled in the subgroup of patients >= 70 years (8.1%). The risk factors for DEP were age >= 70 years (HR 10.19, 95%CI 1.28-80.93), therapy >14 days (7.71, 1.98-30.09) and total cumulative dose of daptomycin >= 10 g (5.30, 1.14-24.66). Conclusions: Clinicians should monitor cumulative daptomycin dosage to minimize DEP risk, and be cautious particularly in older patients when the total dose of daptomycin exceeds 10 g.
引用
收藏
页数:7
相关论文
共 23 条
  • [1] Drug-induced eosinophilic lung disease
    Allen, JN
    [J]. CLINICS IN CHEST MEDICINE, 2004, 25 (01) : 77 - +
  • [2] Drug-induced eosinophilic pneumonia A review of 196 case reports
    Bartal, Carmi
    Sagy, Iftach
    Barski, Leonid
    [J]. MEDICINE, 2018, 97 (04)
  • [3] Pharmacokinetics and tolerability of daptomycin at doses up to 12 milligrams per kilogram of body weight once daily in healthy volunteers
    Benvenuto, Mark
    Benziger, David P.
    Yankelev, Sara
    Vigliani, Gloria
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2006, 50 (10) : 3245 - 3249
  • [4] Daptomycin treatment in patients with resistant staphylococcal periprosthetic joint infection
    Chang, Yu-Jui
    Lee, Mel S.
    Lee, Chen-Hsiang
    Lin, Po-Chun
    Kuo, Feng-Chih
    [J]. BMC INFECTIOUS DISEASES, 2017, 17
  • [5] Organizing pneumonia and pulmonary eosinophilic infiltration associated with daptomycin
    Cobb, Elizabeth
    Kimbrough, Robert C.
    Nugent, Kenneth M.
    Phy, Michael P.
    [J]. ANNALS OF PHARMACOTHERAPY, 2007, 41 (04) : 696 - 701
  • [6] Safety of treatment with high-dose daptomycin in 102 patients with infective endocarditis
    Durante-Mangoni, Emanuele
    Andini, Roberto
    Parrella, Antonio
    Mattucci, Irene
    Cavezza, Giusi
    Senese, Alessandra
    Trojaniello, Claudia
    Caprioli, Roberta
    Diana, Maria Veronica
    Utili, Riccardo
    [J]. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2016, 48 (01) : 61 - 68
  • [7] Daptomycin for treatment of patients with bone and joint infections: a systematic review of the clinical evidence
    Falagas, Matthew E.
    Giannopoulou, Konstantina P.
    Ntziora, Fotinie
    Papagelopoulos, Panayiotis J.
    [J]. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2007, 30 (03) : 202 - 209
  • [8] Hayes Don Jr, 2007, J Infect, V54, pe211, DOI 10.1016/j.jinf.2006.11.006
  • [9] Efficacy and safety of daptomycin for the treatment of infectious disease: a meta-analysis based on randomized controlled trials
    He, Wenqiang
    Zhang, Yawei
    Chen, Hongbin
    Zhao, Chunjiang
    Wang, Hui
    [J]. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2014, 69 (12) : 3181 - 3189
  • [10] Daptomycin-induced Eosinophilic Pneumonia and a Review of the Published Literature
    Higashi, Yoshitsugu
    Nakamura, Shigeki
    Tsuji, Yasuhiro
    Ogami, Chika
    Matsumoto, Kaoru
    Kawago, Koyomi
    Tokui, Kotaro
    Hayashi, Ryuji
    Sakamaki, Ippei
    Yamamoto, Yoshihiro
    [J]. INTERNAL MEDICINE, 2018, 57 (02) : 253 - 258